TD Cowen lowered the firm’s price target on P3 Health Partners (PIII) to $8 from $12.50 and keeps a Hold rating on the shares. The firm updated its model to reflect Q1 results and adjusted its $o.50 target to reflect the company’s 1-for-50 reverse stock split.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PIII:
- P3 Health Partners’ Earnings Call: Strategic Gains Amid Challenges
- P3 Health Partners: Positioned for Growth with Strategic Initiatives and Profitability Improvements
- P3 Health Partners Reports Q1 2025 Financial Results
- P3 Health Partners reports Q1 EPS ($6.28) vs ($7.86) last year
- P3 Health Partners backs FY25 revenue view $1.35B-$1.5B, consensus $1.41B